Bortezomib alleviates experimental pulmonary arterial hypertension

Vascular remodeling and endothelial dysfunction are important pathogenic features of pulmonary arterial hypertension (PAH). There is a growing body of evidence that proteasome inhibitors may be beneficial in vascular diseases by inhibiting proliferation of vascular smooth muscle cells (VSMCs) and am...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of respiratory cell and molecular biology 2012-11, Vol.47 (5), p.698-708
Hauptverfasser:	Kim, Sun-Yong, Lee, Ji-Hyun, Huh, Jin Won, Kim, Hyo Jeong, Park, Mi Kyeong, Ro, Jai Youl, Oh, Yeon-Mok, Lee, Sang-Do, Lee, Yun-Song
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Boronic Acids - pharmacology Boronic Acids - therapeutic use Bortezomib Caspase 3 - metabolism Cell Hypoxia Cell Proliferation - drug effects Cells, Cultured Endothelial Cells - drug effects Endothelial Cells - enzymology Endothelial Cells - physiology Endothelium, Vascular - pathology Heart Ventricles - drug effects Heart Ventricles - enzymology Humans Hypertension, Pulmonary - chemically induced Hypertension, Pulmonary - drug therapy Hypertension, Pulmonary - pathology Liver - drug effects Liver - physiopathology Liver Function Tests Male Mice Mice, Inbred C57BL Monocrotaline Nitric Oxide Synthase Type III - metabolism Proteasome Inhibitors - pharmacology Proteasome Inhibitors - therapeutic use Pulmonary Artery - drug effects Pulmonary Artery - pathology Pulmonary Artery - physiopathology Pyrazines - pharmacology Pyrazines - therapeutic use Rats Rats, Sprague-Dawley
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!